[
    "{\"step_by_step_thinking\": \"Based on the information provided in the documents, tivantinib has shown promising activity in MET-high hepatocellular carcinoma. Multiple studies have reported positive results in terms of time to progression and overall survival in patients with MET-high tumors treated with tivantinib. However, it is important to note that there have been conflicting results from different clinical trials, and some studies have not shown a significant survival benefit. Therefore, while tivantinib has shown potential as a treatment option for MET-high hepatocellular carcinoma, further research and clinical trials are needed to confirm its efficacy.\", \"answer_choice\": \"A\"}"
]